BioWorld Asia

May 21, 2003

Chiron Plans To Pay £542 Million In Cash To Acquire PowderJect

LONDON - Chiron Corp. plans to acquire PowderJect Pharmaceuticals plc in an agreed-to cash offer valuing the vaccines manufacturer at £542 million (US$878 million). (BioWorld International) Read More

EU Officials Call U.S. Complaint On GMOs 'Misguided, Unhelpful'

HIV's Vif Protein Revealed As Potential Therapeutic Target

Germany At Forefront Of Effort For International Cloning Ban

CAT Cuts Staff As Part Of Plan To Concentrate On Development

Seven Organizations Launch Alternative Splicing Project

MedPharma Postpones IPO As Markets Remain Resistant

Transgene Pushing Ahead With Targeted Development Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...